A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.
Advanced Solid Tumors With Homozygous MTAP Deletion
DRUG: BMS-986504|DRUG: [14C]-BMS-986504
Maximum observed concentration (Cmax), Up to 2 weeks|Time of maximum observed drug concentration (Tmax), Up to 2 weeks|Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)), Up to 2 weeks|Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)), Up to 2 weeks|Terminal elimination half-life (T-HALF), Up to 2 weeks|Apparent total body clearance (CLT/F), Up to 2 weeks|Apparent volume of distribution during the terminal phase (Vz/F), Up to 2 weeks|Percentage of estimated part for the calculation of AUC(INF) (%AUC(INF)), Up to 2 weeks|Blood-to-plasma total radioactivity (TRA) ratio, Up to 2 weeks|Total amount of administered dose recovered in urine (UR), Up to 2 weeks|Percent of administered dose recovered in urine (%UR), Up to 2 weeks|Renal clearance (CLR) in urine, Up to 2 weeks|Total radioactivity in UR, Up to 2 weeks|Total radioactivity in %UR, Up to 2 weeks|Total radioactivity in total amount of administered dose recovered in feces (FR), Up to 2 weeks|Total radioactivity in percent of administered dose recovered in feces (%FR), Up to 2 weeks|Total amount of radioactivity recovered (Rtotal), Up to 2 weeks|Total percent of radioactivity recovered (%TOTAL), Up to 2 weeks|TRA amount recovered and fraction of the radioactive dose in vomit if applicable, Up to 2 weeks
Number of participants with adverse events (AEs), Up to 2 years|Number of participants with serious adverse events (SAEs), Up to 2 years|Number of participants with AEs leading to discontinuation, Up to 2 years|Number of participants with drug-related AEs, Up to 2 years|Number of participants with laboratory abnormalities, Up to 2 years|Number of deaths, Up to 2 years
The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.